More than $582 Billion in New U.S. Investment Since 2025
America leads the world in healthcare innovation and access, and a strong medical infrastructure is essential to maintain this standing for our national security.
The world’s pharmaceutical companies are stepping up their investments in America.
We Work For Health’s tracking tool, the U.S. Biopharma Investment Watch, is documenting these developments and providing visibility into the sector's robust expansion and critical role in securing America's position as the global leader in health care innovation. Since January 2025, companies have committed to investing more than $582 billion to bolster U.S. research and development, expand manufacturing, and create jobs across the country.
Investment in America
These investments bring cutting edge treatments closer to the patients who need them while bolstering America’s position as a world leader in healthcare access and innovation. The positive impact of these investments reaches deep into U.S. communities, powering high-skill positions for scientists and engineers, construction and production support roles, and millions of jobs for the communities surrounding the facilities. This builds upon more than 4.9 million total U.S. jobs and $71.6 billion in vendor spending in states along with $2.6B in wages paid to the American construction workforce.
The tracker reflects the sector’s commitment to preserving American leadership in the life sciences, as China continues a coordinated campaign to overtake it.
1,488%
increase in announced U.S. facility investments in 2025 vs 2024
Tens of Thousands
of new construction jobs across America
Faster delivery
of breakthrough medicines to U.S. patients
It’s essential to have the right policies in place that encourage continued investment to secure America’s future as the global leader in life sciences.
U.S. Biopharma Investment Watch
Legend:
Announcement date
Company
Investment amount
Investment location(s)
Jul 21, 2025
Biogen
$2 billion
Wake County-NC, Durham County-NC
With a manufacturing expansion and modernization in the Research Triangle, Biogen looks to enhance its capabilities for gene-targeted therapies – expanding antisense oligonucleotide production and adding new multi-platform fill-finish capacity at both clinical and commercial scales. Advanced automation and AI-driven process controls are part of the upgrades.
May 14, 2025
Sanofi
$20 billion
Unspecified location
Substantially increasing spending on U.S. R&D. Sanofi also announced plans to expand U.S. manufacturing capacity, both through direct investments in Sanofi sites, as well as through partnerships with other domestic manufacturers, to help ensure the production of medicines in the U.S.
May 12, 2025
Roche
$700 million
Holly Springs-NC
The first East Coast manufacturing site for Genentech (Roche’s U.S. subsidiary) is a fill-finish biologics plant that will produce metabolic medicines, including next-gen obesity treatments, to support growing demand.
The project is part of Roche’s $50B U.S. initiative and will create more than 400 local full-time jobs when operational (2029) and about 1,500 construction jobs during development.
May 12, 2025
Roche
$550 million
Indianapolis-IN
Expanding its campus into a major hub for manufacturing continuous glucose monitoring (CGM) systems for diabetes management and adding a new diagnostics production facility.
The expansion is expected to create “hundreds” of skilled manufacturing jobs and thousands of construction jobs in Indiana.
No entries found matching your criteria. Please modify your filters.
Methodology
All investments data comes from publicly available resources. Investments may span across multiple states and, therefore, are reflected on each state page. Investment locations will be updated once specified.
-
Jobs data source: WWFH “in the states” page
-
Labor hours data source: PILMA jobs report page